UNIGE document Scientific Article
previous document  unige:90424  next document
add to browser collection

Ranibizumab for the treatment of degenerative ocular conditions

Triantafylla, Magdalini
Dardabounis, Doukas
Gatzioufas, Zisis
Kozobolis, Vassilios
Ioannakis, Konstantinos
Perente, Irfan
Published in Clinical Ophthalmology. 2014, vol. 8, p. 1187-98
Abstract Degenerative ocular conditions, such as age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, and myopic degeneration, have become a major public health problem and a leading cause of blindness in developed countries. Anti-vascular endothelial growth factor (VEGF) drugs seem to be an effective and safe treatment for these conditions. Ranibizumab, a humanized monoclonal antibody antigen-binding fragment, which inhibits all biologically active isoforms of VEGF-A, is still the gold standard treatment for the majority of these pathological entities. In this review, we present the results of the most important clinical trials concerning the efficacy and safety of ranibizumab for the treatment of degenerative ocular conditions.
PMID: 25028531
Full text
Article (Published version) (284 Kb) - public document Free access
Research group Ophtalmologie expérimentale (925)
(ISO format)
TRIANTAFYLLA, Magdalini et al. Ranibizumab for the treatment of degenerative ocular conditions. In: Clinical Ophthalmology, 2014, vol. 8, p. 1187-98. https://archive-ouverte.unige.ch/unige:90424

47 hits



Deposited on : 2016-12-15

Export document
Format :
Citation style :